Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 205 
Year : 2015  |  Volume : 21  |  Issue : 6  |  Page : 345-354

The new era of hepatitis C virus therapy

Department of Medicine, Multi-Organ Transplant Unit, Western University, London, Ontario, Canada; Department of Medicine, Division of Gastroenterology, King Saud University, Riyadh, Saudi Arabia

Correspondence Address:
Dr. Bandar Al-Judaibi
Western University, 339 Windermere Road, London, Ontario, Canada

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1319-3767.170947

Rights and Permissions

The hepatitis C virus (HCV) has a significant medical and economic impact on societies around the world, and it has been estimated that 130-180 million people are infected with HCV. Therapies for HCV are currently undergoing a revolution. In recent years, several new treatments have been approved by the United States Food and Drug Administration, and many other treatments are in phase II or III clinical trials, including direct antiviral agents (DAAs). Due to recent major advances in the field of HCV therapy, a summary of findings on new HCV therapies are provided in this review article, including reports on new DAAs.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded1924    
    Comments [Add]    

Recommend this journal